Jasper Therapeutics (JSPR, Financial) shared encouraging findings from its SPOTLIGHT Phase 1b/2a trial of subcutaneous briquilimab at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress. The study, focused on adult participants with Chronic Inducible Urticaria (CIndU), demonstrated significant disease control at a 180mg dose.
All 12 participants in this cohort showed a clinical response during the initial 8-week evaluation. Remarkably, 8 participants responded to treatment by the second week, while 7 sustained their response through the eighth week. Briquilimab was well-tolerated, with no serious adverse effects or grade 3 or higher adverse events noted in the study group.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 8 analysts, the average target price for Jasper Therapeutics Inc (JSPR, Financial) is $47.88 with a high estimate of $70.00 and a low estimate of $15.00. The average target implies an upside of 757.97% from the current price of $5.58. More detailed estimate data can be found on the Jasper Therapeutics Inc (JSPR) Forecast page.
Based on the consensus recommendation from 11 brokerage firms, Jasper Therapeutics Inc's (JSPR, Financial) average brokerage recommendation is currently 1.7, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
